 |
| Contact us |
|
| For media professionals: |
This contact information is for media professionals only. If you are not a member of the news media, please contact us via the phone number or email link at the bottom of the page.
|
|
| U.S. Communications: |
Lisa Buffington
(908) 981-6569
US.media-relations@sanofi-aventis.com
sanofi-aventis U.S.
55 Corporate Drive
Bridgewater, NJ 08807
Tel: 800-981-2491
|
| Via email |
|
|
|
|
 | 2009 Press Releases |
|
 | Press releases are intended for journalists, investors and shareholders. |
|
|
|
| December 21, 2009 |
| Sanofi-aventis to Acquire Chattem Inc. Creating a Strong U.S. Consumer Healthcare Platform |
|
|
|
|
| December 11, 2009 |
| New Executive Leadership and CEO Announced for BiPar Sciences |
|
|
|
|
| November 30, 2009 |
| Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America |
|
|
|
|
| November 19, 2009 |
| New GoMeals™ iPhone Application from sanofi-aventis U.S. to Help People with Diabetes Eat Healthy Anywhere, Anytime |
|
|
|
|
| October 30, 2009 |
| Sanofi-aventis Delivers a Solid Performance in Third Quarter 2009 |
|
|
|
|
| October 29, 2009 |
| Sanofi-aventis U.S. Appoints Patrick McLain Vice President, U.S. Federal Government Affairs and Policy |
|
|
|
|
| October 16, 2009 |
| FDA Approves Elitek® (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy |
|
|
|
|
| September 29, 2009 |
| Sanofi-aventis launches major insulin research program in partnership with the international scientific community |
|
|
|
|
| September 16, 2009 |
| Health Leaders Issue Recommendations to Improve Management of a Common, Costly and Misunderstood Cardiovascular Disease: Atrial Fibrillation |
|
|
|
|
| August 27, 2009 |
| Sanofi-aventis U.S. Announces Closure of Kansas City Manufacturing Site |
|
|
|
|
| August 24, 2009 |
| FDA Approves XYZAL® for Use in Children Age Six Months and Older for the Relief of Perennial Allergic Rhinitis and Chronic Idiopathic Urticaria |
|
|
|
|
| August 17, 2009 |
| Real-World Study Showed Cost Savings for VTE Prophylaxis with Enoxaparin Compared with Unfractionated Heparin (UFH) |
|
|
|
|
| August 05, 2009 |
| Sanofi-aventis Recognized for Workplace Efforts to Prevent Cancer |
|
|
|
|
| August 05, 2009 |
| The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S. |
|
|
|
|
| August 04, 2009 |
| Sanofi-aventis U.S. Introduces BenzaClin® Carekit |
|
|
|
|
| July 29, 2009 |
| FDA Approves Sculptra®Aesthetic, A Facial Injectable for Correction of Nasolabial |
|
|
|
|
| July 29, 2009 |
| Sanofi-aventis Announces Second Quarter 2009 Results |
|
|
|
|
| July 28, 2009 |
| MULTAQ® (dronedarone) for Atrial Fibrillation or Atrial Flutter Now Available in the United States |
|
|
|
|
| July 15, 2009 |
| Expert Statement Issued about Lantus® Following Recent Publications in Diabetologia |
|
|
|
|
| July 02, 2009 |
| FDA Approves Multaq® for Patients with Atrial Fibrillation or Atrial Flutter |
|
|
|
|
| June 06, 2009 |
| New Study Showed Lantus® Plus One, Two or Three Shots of Apidra® Lowered Patients’ Blood Sugar |
|
|
|
|
| June 06, 2009 |
| New Pooled Analysis Found Lantus® Reduced A1C and FBG Levels in Adults Over 65 with Type 2 Diabetes Compared to Those Treated with NPH |
|
|
|
|
| May 28, 2009 |
| Sanofi-aventis U.S. Announces Settlement of Medicaid “Best Price” Investigation |
|
|
|
|
| May 11, 2009 |
| Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment |
|
|
|
|
| April 21, 2009 |
| Today on Capitol Hill: The Malaria Forum |
|
|
|
|
| April 21, 2009 |
| American Performing Icon Ben Vereen Encourages People to “Take the Stage” and Act on Their Diabetes in 2009 |
|
|
|
|
| April 21, 2009 |
| AcneHeroes.com Puts Focus on Skin Care for Prom |
|
|
|
|
| April 20, 2009 |
| Apidra® SoloSTAR®, the Easy-to-Use Insulin Delivery Device from sanofi-aventis, Now Available in the United States |
|
|
|
|
| April 07, 2009 |
| Aplenzin™, The Only Single Tablet Once-Daily Treatment for Depression At All Doses, Now Available in the United States |
|
|
|
|
| March 18, 2009 |
| FDA Advisory Committee Recommends Approval of Multaq® (dronedarone) |
|
|
|
|
| March 16, 2009 |
| Paul Chew appointed to sanofi-aventis U.S. Chief Science Officer/Chief Medical Officer |
|
|
|
|
| March 06, 2009 |
| Sanofi-aventis and Æterna Zentaris Sign Agreement in the U.S. |
|
|
|
|
| February 26, 2009 |
| FDA Approves Apidra® SoloSTAR® - A Prefilled Disposable Insulin Pen |
|
|
|
|
| February 24, 2009 |
| Sanofi-aventis U.S. Chairman Tim Rothwell to Retire after an Outstanding Career |
|
|
|
|
| February 11, 2009 |
| New England Journal of Medicine Publishes Results from the Landmark ATHENA Trial with Multaq® (dronedarone) in Atrial Fibrillation |
|
|
|
|
| February 05, 2009 |
| Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus® and Rapid-Acting Insulin Apidra® |
|
|
|
|
| February 03, 2009 |
| New Diabetes Resource Provides Tools and Support to Families of Newly-Diagnosed Children with Type 1 Diabetes |
|
|
|
|
| January 29, 2009 |
| Alliance of Experts Created to Help Raise Awareness of Best Practices in Diabetes Treatment |
|
|
|
|
| January 22, 2009 |
| Sanofi-aventis Partners with the African American Community in Memphis to Increase Health Awareness, Access to Resources and Help Improve Patient Care |
|
|
|
|
|
|
